La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Pieris Pharmaceuticals Gestion
Gestion contrôle des critères 3/4
Le PDG Pieris Pharmaceuticals' est Steve Yoder, nommé en Dec2014, a un mandat de 9.67 ans. La rémunération annuelle totale est $ 1.36M, composée du salaire de 43% et des bonus 57%, y compris les actions et options de la société. détient directement 0.006% des actions de la société, d'une valeur de $ 1.27K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.9 ans et 6.8 ans.
Informations clés
Steve Yoder
Directeur général
US$1.4m
Rémunération totale
| Pourcentage du salaire du PDG | 43.0% |
| Durée du mandat du directeur général | 9.8yrs |
| Propriété du PDG | 0.006% |
| Durée moyenne d'occupation des postes de direction | 5yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.9yrs |
Mises à jour récentes de la gestion
Recent updates
The Market Doesn't Like What It Sees From Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Revenues Yet As Shares Tumble 30%
Jul 11
Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 27% Share Price Plunge
Apr 21We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Mar 19Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Not Doing Enough For Some Investors As Its Shares Slump 27%
Dec 18We Think Pieris Pharmaceuticals (NASDAQ:PIRS) Needs To Drive Business Growth Carefully
Aug 18Analysts Just Shaved Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts Dramatically
May 15Why Investors Shouldn't Be Surprised By Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) 41% Share Price Plunge
Apr 17Can Pieris Pharmaceuticals (NASDAQ:PIRS) Afford To Invest In Growth?
Dec 31Bearish: This Analyst Is Revising Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Revenue and EPS Prognostications
Aug 10Pieris Pharmaceuticals GAAP EPS of -$0.14 misses by $0.03, revenue of $3.7M misses by $6.77M
Aug 04Pieris: Early Stage Developer Of Novel Asset Class
Jan 09We're Not Very Worried About Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Dec 15Progress At Pieris Pharmaceuticals
Oct 27Analysts Just Made A Noticeable Upgrade To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Forecasts
Aug 05We Think Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Compensation Package Needs To Be Put Under A Microscope
Jun 19Need To Know: Analysts Just Made A Substantial Cut To Their Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Estimates
May 22Will Pieris Pharmaceuticals (NASDAQ:PIRS) Spend Its Cash Wisely?
May 19Analysts Are Betting On Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) With A Big Upgrade This Week
Apr 01Here's What Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shareholder Ownership Structure Looks Like
Mar 08We're Keeping An Eye On Pieris Pharmaceuticals' (NASDAQ:PIRS) Cash Burn Rate
Feb 01How Much Did Pieris Pharmaceuticals'(NASDAQ:PIRS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Dec 28
How Does Pieris Pharmaceuticals' (NASDAQ:PIRS) CEO Salary Compare to Peers?
Dec 02Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$24m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$585k | -US$25m |
| Sep 30 2023 | n/a | n/a | -US$28m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$41m |
| Dec 31 2022 | US$2m | US$565k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$35m |
| Jun 30 2022 | n/a | n/a | -US$42m |
| Mar 31 2022 | n/a | n/a | -US$47m |
| Dec 31 2021 | US$2m | US$548k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$51m |
| Jun 30 2021 | n/a | n/a | -US$48m |
| Mar 31 2021 | n/a | n/a | -US$38m |
| Dec 31 2020 | US$2m | US$535k | -US$37m |
| Sep 30 2020 | n/a | n/a | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$15m |
| Mar 31 2020 | n/a | n/a | -US$22m |
| Dec 31 2019 | US$2m | US$515k | -US$28m |
| Sep 30 2019 | n/a | n/a | -US$36m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$28m |
| Dec 31 2018 | US$3m | US$500k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$8m |
| Mar 31 2018 | n/a | n/a | -US$18m |
| Dec 31 2017 | US$1m | US$450k | -US$18m |
Rémunération vs marché: La rémunération totale de Steve ($USD 1.36M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).
Rémunération et revenus: La rémunération de Steve a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Steve Yoder (48 yo)
9.8yrs
Titularisation
US$1,358,952
Compensation
Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 9.8yrs | US$1.36m | 0.0057% $ 1.2k | |
| Senior VP | 5yrs | US$729.04k | 0.018% $ 3.9k | |
| Senior VP & Chief Development Officer | no data | US$705.45k | 0.0044% $ 936.6 | |
| Executive Director of Investor Relations | no data | pas de données | pas de données | |
| Chief Supply Chain Officer | 4.9yrs | pas de données | pas de données |
5.0yrs
Durée moyenne de l'emploi
48yo
Âge moyen
Gestion expérimentée: L'équipe dirigeante de PIRS est chevronnée et expérimentée (5 années d'ancienneté moyenne).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 9.8yrs | US$1.36m | 0.0057% $ 1.2k | |
| Independent Chairman | 7.3yrs | US$94.09k | 0.019% $ 4.0k | |
| Independent Director | 9.8yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 8yrs | US$72.58k | 0.019% $ 4.0k | |
| Independent Director | 6yrs | US$65.08k | 0% $ 0 | |
| Independent Director | 5.9yrs | US$53.09k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$52.09k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$52.09k | 0% $ 0 | |
| Member of Clinical & Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Clinical & Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Clinical & Scientific Advisory Board | no data | pas de données | pas de données | |
| Member of Clinical & Scientific Advisory Board | no data | pas de données | pas de données |
6.9yrs
Durée moyenne de l'emploi
61.5yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de PIRS sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).